Spotlight report on molecular testing in advanced lung cancer
This spotlight audit investigates the efficacy and outcomes of molecular testing in patients with advanced non-small-cell lung cancer (NSCLC) in England covering 1,157 patients.
CONCLUSION: In decision-making between segmentectomy and lobectomy, adequate margins are required for the selection of segmentectomy, the most common of which is LUL trisegmentectomy. Technical challenges can be overcome with adequate training and simulation. Additional research could focus on the identification of factors associated with recurrence. PMID: 32097983 [PubMed - as supplied by publisher]
Conditions: Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 Interventions: Biological: Necitumumab; Drug: Osimertinib; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Biological: Trastuzumab Sponsors: Jonsson Comprehensive Cancer&...
Publication date: Available online 26 February 2020Source: Respiratory InvestigationAuthor(s): Miho Tanaka, Tatsuya Ishii, Rie Tohnai, Shoichi Itoh, Yoshitaka Kawa, Yuko Kono, Yoshiko Urata, Yoshihiro Hattori, Miyako Satouchi
CONCLUSIONS: Our results indicated that HOXA-AS2 could enhance the migration and invasion abilities of NSCLC by targeting miR-145-3p. Furthermore, these findings suggested that HOXA-AS2 might be a potential therapeutic target for NSCLC. PMID: 32096154 [PubMed - in process]
CONCLUSIONS: LncRNA TRERNA1 was up-regulated both in NSCLC tissues and cell lines. Its level was associated with pathological stage and poor prognosis in NSCLC. In addition, lncRNA TRERNA1 could promote the malignant progression of NSCLC via modulating FOXL1. PMID: 32096153 [PubMed - in process]
Conclusions: We found that recent recurrence, oligo-recurrence, and DLT were associated with an improved median PR-PFS time and long-term PR-PFS rate in patients with postoperative recurrence after complete resection of NSCLC. On the basis of these results, we believe that DLT should be considered first for patients with oligo-recurrence before applying noncurative treatment.
This article provides an overview of the current state of knowledge of the clinical experience using radiation therapy in combination with immune therapy and discusses the rationale for integrating these 2 modalities in the treatment of advanced non–small cell lung cancer. Available data supports the use of radiation therapy in combination with immunotherapy to achieve improved local and systemic tumor control. Evidence from the early clinical trials has shown that using radiation therapy and immune checkpoint blockade therapies together produces a greater clinical effect than using either modality alone. To maximize...
(University of Pennsylvania School of Medicine) Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.
Conclusion: Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities.
Conclusions: SBRT results in excellent local control (LC) and acceptable survival in medically inoperable ES-NSCLC with minimal adverse effects. Charlson comorbidity index and target volume are important prognostic factors and may aid in patient selection.